The effect of atorvastatin on lung function and morbidity as add-on therapy in asthmatic patients. A double-blind randomized cross-over trial.

Completed

• Conditions: Moderate to severe persistent asthma; Respiratory - Asthma

• Registration Number: ACTRN12607000179437
• Lead Sponsor: Shaheed Beheshti University of Medical Sciences, Iran

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-03-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

Persistent moderate to severe asthma

Exclusion Criteria

Dyslipidemia, adverse effect due to atorvastatin, other comorbid condition (heart failure, diabetes, MI, hypertension), receiving medication(s) interact with atorvastatin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in Forced Expiratory Volume in one second (FEV1)[At baseline and after 4 weeks of each intervention (placebo or atorvastatin therapy)];Changes in Forced Vital Capacity (FVC)[At baseline and after 4 weeks of each intervention (placebo or atorvastatin therapy)];Changes in Peak Expiratory Flow (PEF)[At baseline and after 4 weeks of each intervention (placebo or atorvastatin therapy)]

Secondary Outcome Measures

Name	Time	Method
Changes in score of Jones Index of Morbidity[At baseline and after 4 weeks of each intervention (placebo or atorvastatin therapy).]